[Insightec in PR Newswire] Insightec announces FDA approval of staged bilateral focused ultrasound treatment for Parkinson’s disease

uttu
0 Min Read


HAIFA, Israel and MIAMIJuly 8, 2025 /CNW/ — Insightec, a global healthcare innovator dedicated to using focused ultrasound to transform patient care, announced today that the U.S. Food and Drug Administration (FDA) has approved the use of its Exablate Neuro platform for staged bilateral pallidothalamic tractotomy treatment in patients living with advanced Parkinson’s disease (PD).

Read more here.

Share This Article
Leave a Comment